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Abstract
Background: Data comparing duloxetine with existing antidepressant treatments is limited. A
comparison of duloxetine with fluoxetine has been performed but no comparison with venlafaxine,
the other antidepressant in the same therapeutic class with a significant market share, has been
undertaken. In the absence of relevant data to assess the place that duloxetine should occupy in
the therapeutic arsenal, indirect comparisons are the most rigorous way to go.
We conducted a systematic review of the efficacy of duloxetine, fluoxetine and venlafaxine versus
placebo in the treatment of Major Depressive Disorder (MDD), and performed indirect
comparisons through meta-regressions.
Methods: The bibliography of the Agency for Health Care Policy and Research and the CENTRAL,
Medline, and Embase databases were interrogated using advanced search strategies based on a
combination of text and index terms. The search focused on randomized placebo-controlled
clinical trials involving adult patients treated for acute phase Major Depressive Disorder. All
outcomes were derived to take account for varying placebo responses throughout studies. Primary
outcome was treatment efficacy as measured by Hedge's g effect size. Secondary outcomes were
response and dropout rates as measured by log odds ratios. Meta-regressions were run to
indirectly compare the drugs. Sensitivity analysis, assessing the influence of individual studies over
the results, and the influence of patients' characteristics were run.
Results: 22 studies involving fluoxetine, 9 involving duloxetine and 8 involving venlafaxine were
selected. Using indirect comparison methodology, estimated effect sizes for efficacy compared with
duloxetine were 0.11 [-0.14;0.36] for fluoxetine and 0.22 [0.06;0.38] for venlafaxine. Response log
odds ratios were -0.21 [-0.44;0.03], 0.70 [0.26;1.14]. Dropout log odds ratios were -0.02 [-
0.33;0.29], 0.21 [-0.13;0.55]. Sensitivity analyses showed that results were consistent.
Conclusion:  Fluoxetine was not statistically different in either tolerability or efficacy when
compared with duloxetine. Venlafaxine was significantly superior to duloxetine in all analyses
except dropout rate. In the absence of relevant data from head-to-head comparison trials, results
suggest that venlafaxine is superior compared with duloxetine and that duloxetine does not
differentiate from fluoxetine.
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Background
Duloxetine is a selective serotonin and norepinephrine
reuptake inhibitor (SNRI) that claims greater affinity for
the serotonin and norepinephrine transporters compared
with venlafaxine [1,2]. The efficacy and safety of duloxet-
ine in the treatment of major depressive disorder (MDD)
in adults (18–65 years) has been evaluated in 9 phase II
and III clinical trials [3-5]. All were randomized, double
blind, placebo-controlled studies with doses ranging from
40 to 120 mg/day in the acute treatment of MDD. Results
have shown that duloxetine provided relief from psycho-
logical symptoms of depression compared with placebo.
Six of the above studies used an active comparator: either
fluoxetine or paroxetine. None, however, was designed
and powered for direct head-to-head comparison between
duloxetine and the active comparator. Inclusion of a selec-
tive serotonin reuptake inhibitor (SSRI) was intended
only to show non-inferiority of duloxetine. No trial has
used venlafaxine, the other marketed SNRI, as an active
comparator.
The amount of data comparing duloxetine with existing
antidepressant treatments is quite limited. The lack of
direct comparisons between the recommended daily dose
(60 mg) and an active comparator was criticised in a
recent evaluation of duloxetine by the Committee for
Medicinal Products for Human Use (CHMP) [6]. Assess-
ments of the benefit/risk ratio of a new drug compared
with a standard drug at an adequate dose are generally
required and it is recommended that clinical trials be con-
ducted not only against placebo, but also against active
comparators [7]. The aim of such studies may be to show
superiority over the active comparator or to demonstrate
that at least a similar balance between benefit and risk
exists when the drug of interest is compared with another
acknowledged standard antidepressant.
In the absence of head-to-head randomized studies, indi-
rect comparisons can be made between molecules. Clini-
cal trials frequently compare efficacy of a drug versus
placebo in the treatment of MDD. Less frequent, however,
are head-to-head comparisons. Indirect comparisons tak-
ing into account all available placebo-controlled studies
are capable of obtaining an effect size and a confidence
interval of the difference between two compounds. The
algorithm used gives results adjusted for discrepancies in
sociodemographics, settings and designs.
After conducting a systematic review of the efficacy of
duloxetine, fluoxetine and venlafaxine versus placebo in
the treatment of MDD we performed an indirect compar-
ison of the benefits of duloxetine versus fluoxetine and
venlafaxine. We used meta-regression analysis to test
whether or not differences in effectiveness (which cannot
be explained by the differences in settings only) exist
between fluoxetine and duloxetine on one hand and ven-
lafaxine and duloxetine on the other.
Methods
The analyses sets
We used advanced search strategies based on a combina-
tion of text and index terms to interrogate the CENTRAL,
Medline and Embase databases as well as the bibliogra-
phy of the US Agency for Health Care Policy and Research
(AHCPR). The bibliography from the AHCPR is an
exhaustive literature search (both published and non-
published) of trials in depression up to 1999.
Selection criteria were: study reporting HAMD results in
randomised trials with a placebo arm, involving adult
patients suffering from MDD (as assessed by DSM (III, III-
R, IV)) treated in acute phase with either fluoxetine, ven-
lafaxine, duloxetine. Excusion criteria were presence of
comorbidities; absence of the HAMD scale; involving ado-
lescents, children or elderly; absence of randomisation
and absence of a placebo arm.
These criteria were considered sufficient to retrieve all
studies of interest to be included in the analysis set.
Two research assistants independently selected papers by
reading the abstract and, if necessary, the entire article to
assess eligibility and data extraction. Careful re-reading of
the papers resolved differences between each author anal-
ysis set and letters were sent to corresponding authors in
the attempt to reduce missing data.
Publication bias was assessed drawing funnel plots, and
Egger Test was used to test funnel plot asymmetry.
Statistical outcomes
Because different trials do not necessarily use the same
scale and/or version for assessing efficacy, an effect size
was derived from the primary outcome of each study
(either HAM-D 17 21 or 24). This enabled deriving a com-
mon effect measure across studies that used different
scales. The effect size was Hedge's g  (a Standardised
Response Mean estimator), which was corrected for small
sample size bias. To compute an effect size, both the mean
and an estimate of dispersion (variance, standard devia-
tion) have to be present. When the dispersion was miss-
ing, data was imputed using the sample size weighted
method [8]. If both mean and dispersion were missing,
the study was removed from the analysis set.
The computed effect sizes were adjusted for severity at
baseline to account for differences in patients' groups
(selection bias).BMC Psychiatry 2006, 6:30 http://www.biomedcentral.com/1471-244X/6/30
Page 3 of 15
(page number not for citation purposes)
The effect size was defined as the difference between the
mean change in depression scale score from baseline to
end-of-study in the active arm and the mean change in
depression scale score from baseline to end of study in the
placebo arm; divided by the standard deviation of the dif-
ference.
Other endpoints were response and dropout rates.
Response was defined as a reduction of at least 50% in the
HAM-D score from baseline. Dropouts were considered
regardless of cause, which gave a rough indicator of the
tolerability and safety and efficacy of the treatment. In
other words, dropouts were an indicator of failures of the
present therapy.
The response and dropouts rates were analysed using log-
odds ratios. A log-odds ratio equal to zero indicated that
there was no statistical difference between the two com-
pared groups. Considering the response rate, a value
greater than zero indicated that more patients in the treat-
ment group were classified as responders, and therefore
that the treatment was better compared with the reference
(placebo or duloxetine). A value lower than zero indi-
cated that the reference (placebo or duloxetine) was bet-
ter. Regarding dropouts, a value greater than zero
indicated that more patients in the reference group (pla-
cebo or duloxetine) withdrew, and therefore that the treat-
ment was better (in terms of efficacy and/or safety)
compared with the reference (placebo or duloxetine). A
value lower than zero indicated that treatment was less
effective or less tolerated than the reference (placebo or
duloxetine).
Statistical methods
Random-effect meta-analyses were computed for each
outcome and each treatment compared with placebo.
Mean age, mean percentage of male, mean study duration
and range of dosage were computed for each treatment.
Following recommendations by Glenny et al. [9] and van
Houwelingen et al. [10], a mixed procedure was run. This
enabled handling studies with more than two arms (typi-
cally when different dosages are included in the same
study), as well as studies presenting two drugs in the same
trial (two trials assessed the effectiveness of duloxetine
versus placebo and were fluoxetine controlled). The
method used is a weighted least squares algorithm which
iteratively computes a between-study variance while keep-
ing each within-study variance constant. Therefore, what
are modelled by default (when no adjustment is made)
are drug effect (an antidepressant effect of the drugs) and
drug-specific effect. The drug specific effect is the effect
tested between the two treatments compared.
The models were computed under SAS PROC MIXED
[11]. This procedure gives also good coverage for confi-
dence intervals according to van Houwelingen et al. [10].
As in van Houwelingen et al., [10] Wald confidence inter-
vals were used.
Sensitivity analyses were planned a priori and included:
Performing several adjustments. The variables chosen a
priori as having a potential influence over the outcome of
a study were age, male percentage, duration of study and
dosage. Robustness was then assessed observing the vari-
ation in the estimation of the outcome, its corresponding
confidence interval, as well as the size of the estimated
residual between-study variance [10]. An adjustment over
the fact that the effect size was imputed was also run (in
case the dispersion had to be imputed to compute an
effect size). To assess its influence over the results, studies
were removed from the analysis set one at a time. A post
hoc. sensitivity analysis was run on a subgroup of fluoxet-
ine studies excluding the studies where the number of
patients was below 20.
The following rules were applicable for all computed
models:
￿ In case an adjustment factor was missing, it was imputed
by the corresponding weighted mean computed with
available data.
￿ Influence of missing data was computed through sensi-
tivity analyses by removing the studies where the data was
missing.
￿ IIn the event that an outcome was missing and no reply
was received from the letters sent, the study was removed
from the analysis set for the particular analysis for which
the outcome was missing.
Results
No precise answers were received from the letters sent to
corresponding authors; therefore, the number of missing
data remained unchanged.
Individual studies results
For duloxetine, 8 publications showing results for 9 trials
(each with varying characteristics) were selected, [Figure
1]. [Table 1] matches the publications with the informa-
tion available from each trial. Mean age varied from 41 to
45 and the percentage of males varied from 25 to 40%.
Duration of treatment varied from 8 to 9 weeks and dos-
ages (fixed or variable) were from 40 to 120 mg per day.
The effect size comparing duloxetine to placebo was -
0.29(0.15). The response and dropouts log odds ratio
were 0.58(0.18) and -0.02(0.32) respectively. The funnel
plot shape cannot rule out the possibility of a publicationBMC Psychiatry 2006, 6:30 http://www.biomedcentral.com/1471-244X/6/30
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bias; see [Figure 4]. The Funnel plot was not statistically
significantly asymmetrical according to the Egger test (p =
0.9).
For fluoxetine, 22 papers were selected [Figure 2], present-
ing a rather heterogeneous picture [Table 2]. Mean age
varied from 33 to 47 and the percentage of males varied
from 26 to 57%. Duration of treatment varied from 5 to
12 weeks and dosages (fixed or variable) were from 20 to
80 mg per day. It is worth noting that some studies
include few patients (from 5 to 169). The effect size com-
paring fluoxetine to placebo was -0.46(0.52). The
response and dropouts log odds ratio were 0.37(0.32) and
-0.02(0.23), respectively. A positive point worth noting is
that publication bias is shown to be minimised (see Fig-
ure 4). This figure shows the typical conic shape centred
Diagram Flow for duloxetine Figure 1
Diagram Flow for duloxetine.
Potentially relevant articles identified and 
screened for retrieval  (n=34) 
Excluded articles (n=22) 
Reasons: 
- not right population 
- placebo was not included as a 
reference 
- long-term study 
articles retrieved for more detailed evaluation 
(n=12) 
Excluded articles (n=4) 
Reasons: 
-  Other types of depression: 
Poststroke, seasonal, 
melancholia…
-  Studies with pooled data 
- Studies  with  co-therapy 
-  Studies with no placebo arm 
-  Other problem design: open trials, 
continuation treatment with new 
formulations, fuoxetine 
discontinuated, prediction 
Studies…
articles selected for evaluation (n=8) 
RCTs selected by outcome 
Efficacy (n=8) 
Response (n=6) 
Dropouts (n=5) 
Excluded articles  
Reasons: 
- Missing data BMC Psychiatry 2006, 6:30 http://www.biomedcentral.com/1471-244X/6/30
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over the value estimated which indicates little or no bias.
The Funnel plot was not statistically significantly asym-
metrical according to the Egger test (p = 0.4).
For venlafaxine, 8 papers were selected, see [Figure 3], with
the following characteristics [Table 3]. Mean age varied
from 40 to 46 and the percentage of males varied from 31
to 60%. Duration of treatment varied from 6 to 12 weeks
and the dosages (fixed or variable) were from 75 to 225
mg per day. The effect size comparing venlafaxine to pla-
cebo was -0.51(0.20). The response and dropouts log
odds ratio were 1.28(0.64) and -0.25(0.32), respectively.
The funnel plot shape cannot rule out the possibility of all
publication bias [Figure 4]. The Funnel plot was not statis-
tically significantly asymmetrical according to the Egger
test (p = 0.1).
Meta-regressions: duloxetine compared with active 
comparators
For duloxetine compared with fluoxetine, the estimated effect
size was 0.11 [-0.14;0.36] for the treatment effect (Figure
5a). The estimated response log odds ratio was -0.21 [-
0.44;0.03] (Figure 5b) (only 13 fluoxetine studies and 6
duloxetine studies were included because of missing data)
with a corresponding odds ratio of 0.81. The estimated
dropouts log odds ratio was -0.02 [-0.33;0.29] (Figure 5c)
(only 8 fluoxetine studies and 5 duloxetine studies were
included because of missing data). None of these results
vs. fluoxetine were significant, although a trend can be
seen in favor of duloxetine in term of number of respond-
ers.
For duloxetine compared with venlafaxine, the estimated
effect size was 0.22 [0.06;0.38] for the treatment effect
(Figure 5a), demonstrating a significant better efficacy of
venlafaxine compared with duloxetine. The estimated
response log odds ratio was 0.70 [0.26;1.14] also signifi-
cantly different in favour of venlafaxine (Figure 5b) (only
6 venlafaxine studies and 6 duloxetine studies were
included because of missing data). The estimated dropout
log odds ratio was 0.21 [-0.13;0.55] (Figure 5c) (only 7
venlafaxine and 5 duloxetine studies were included
because of missing data). Venlafaxine seem more effica-
cious both in reduction of symptoms and in term of
number of responders (the corresponding odds ratio is
2.01) for a similar safety profile.
Table 1: Selected studies presentation for duloxetine
Study Inclusion criteria Age Percent 
male
Duration 
(weeks)
Treatment Dosage 
(mg/day)
Patients 
per arm
Effect size 
(SD)
Response 
(%)
Dropouts 
(%)
Goldstein et al. [9] DSM-IV, Age 18–
65
HAM-D17 ≥ 15, 
CGI-S ≥ 4
42 0.34 8 Duloxetine
Placebo
40–120 70
70
-0.3(0.03) 0.64
0.48
0.34
0.34
Detke et al. [10] DSM-IV, Age ≥ 18
HAM-D17 ≥ 15, 
CGI-S ≥ 4
42 0.33 9 Duloxetine
Placebo
60 123
122
-0.6(0.02) 0.62
0.29
Detke et al. [12] DSM-IV, Age ≥ 18
HAM-D17 ≥ 15, 
CGI-S ≥ 4
41 0.31 9 Duloxetine
Placebo
60 128
139
-0.2(0.02) 0.65
0.42
0.39
0.35
Detke et al. [13] DSM-IV, Age ≥ 18
HAM-D17 ≥ 15, 
CGI-S ≥ 4
45
43
0.26
0.25
8 Duloxetine
Duloxetine
Placebo
80
120
95
93
93
-0.3(0.02)
-0.6(0.02)
0.65
0.71
0.44
0.13
0.10
0.19
Goldstein et al. [14] DSM-IV, Age ≥ 18
HAM-D17 ≥ 15, 
CGI-S ≥ 4
41
41
0.4
0.38
8 Duloxetine
Duloxetine
Placebo
40
80
86
91
89
-0.4(0.02)
-0.5(0.02)
0.54
0.60
0.30
0.36
0.42
0.42
Greist et al. [4]
Falissard et al. [3]
DSM-IV, Age ≥ 18 8 Duloxetine
Placebo
120 82
75
-0.1(0.03)
Greist et al. [4]
Falissard et al. [3]
DSM-IV, Age ≥ 18 8 Duloxetine
Duloxetine
Placebo
40
80
91
84
90
-0.2(0.02)
-0.4(0.02)
Greist et al. [4]
Falissard et al. [3]
DSM-IV, Age ≥ 18 8 Duloxetine
Duloxetine
Placebo
80
120
93
103
99
-0.3(0.02)
-0.3(0.02)
Brannan et al. [5] DSM-IV, Age ≥ 18
HAM-D17 ≥ 15, 
CGI-S ≥ 4
41 0.35 9 Duloxetine
Placebo
60 141
141
-0.2(0.02) 0.42
0.40
0.16
0.09
Globally 42 (1) 0.33 8 (0.4) Duloxetine
Placebo
20–120 1280
918
-0.29(0.05) 0.58(0.09
) **
-
0.02(0.16
) **
** Log Odds ratios (SD)BMC Psychiatry 2006, 6:30 http://www.biomedcentral.com/1471-244X/6/30
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Sensitivity analyses
For duloxetine compared with fluoxetine, cf. [Table 4] either
investigating the primary outcome (efficacy as measured
by derived HAMD scale) or the response factor, the results
were stable through adjustments, no amelioration in the
adjustment was reached (the residual between-study vari-
ance estimate remained approximately constant), and
confidence intervals remained large and stable. The effect
size of the best prediction (smallest residual between-
study variance) was 0.12 [-0.14;0.38]. The odds ratio of
the response factor varied from 0.81 to 0.95, favouring
numerically duloxetine in every analysis and reaching
borderline significance when the estimate was close to
0.81. The residual between-study variance was constant.
Concerning the dropout factor, the odds ratio varied from
1.21 to 1.40, numerically favouring fluoxetine in every
analysis. Adjusting for duration of the study revealed a sig-
nificant advantage in favour of fluoxetine (corresponding
Diagram Flow for fluoxetine Figure 2
Diagram Flow for fluoxetine.
Potentially relevant RCTs identified and 
screened for retrieval  (n=293) 
Excluded articles (n=161) 
Reasons: 
-  not right population 
-  placebo was not included as a 
reference 
RCTs retrieved for more detailed evaluation 
(n=132) 
Excluded articles (n=110) 
Reasons: 
-  Other types of depression: 
Poststroke, seasonal, 
melancholia…
-  Studies with pooled data 
-  Studies with co-therapy 
-  Studies with no placebo arm 
- Other  problem design: open trials, 
continuation treatment with new 
formulations, fuoxetine 
discontinuated, prediction 
Studies…
RCTs selected for evaluation (n=22) 
RCTs selected by outcome 
Efficacy (n=22) 
Response (n=13) 
Dropouts (n=8) 
Excluded articles  
Reasons: 
-  Missing data B
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Table 2: Selected studies presentation for fluoxetine
Study Inclusion criteria Age Percent 
male
Duration 
(weeks)
Treatment Dosage (mg/day) Patients 
per arm
Effect size (SD) Response (%) Dropout (%)
Fabre et al. [15] Age 21–70
HAM-D ≥ 20
5 Fluoxetine
Placebo
40–80 22
26
-0.8 (0.1) 0.50
0.44
Stark et al. [16] DSM-III, Age 18–70
HAM-D21 ≥ 20
40 0.32 6 Fluoxetine
Placebo
20–80 185
169
-0.3(0.01) 0.63
0.38
0.37
0.45
Cohn et al. [17] DSM-III, Age 20–64
HAM-D ≥ 20
41 0.40 6 Fluoxetine
Placebo
20–80 54
57
-1.3(0.04) 0.72
0.30
0.30
0.72
Fieve et al. [18] DSM-III, Age 18–65
HAM-D21 ≥ 20
0.57 6 Fluoxetine
Fluoxetine
Fluoxetine
Placebo
5
20
40
14
13
13
9
-0.5 (0.1)
Rickels et al. [19] DSM-III, Age 21–70
HAM-D ≥ 20
47.2 0.21 5 Fluoxetine
Placebo
20–80 18
24
-0.7 (0.2) 0.90
0.39
Goodnick et al. [20] DSM-III, Age 18–65
HAM-D ≥ 116
0.54 7 Fluoxetine
Placebo
20–60 30
5
-1.1(0.3)
0.1(0.2)
Wernicke et al. [21] DSM-III, Age 18–65
HAM-D ≥ 20
39.8 0.43 6 Fluoxetine
Fluoxetine
Fluoxetine
Placebo
20
40
60
97
97
103
48
-0.5(0.03)
-0.5(0.03)
-0.2(0.03)
0.53
0.61
0.48
0.27
0.38
0.40
0.55
0.44
Fabre et al. [22] DSM-III, Age 18–65
HAM-D ≥ 14
6 Fluoxetine
Fluoxetine
Fluoxetine
Placebo
20
40
60
22
25
25
12
-2.1 (0.4)
-1.5 (0.3)
-2.3 (0.5)
0.67
0.31
1
0
Wernicke et al. [23] DSM-III, Age 18–65
HAM-D ≥ 14
39 0.37 6 Fluoxetine
Fluoxetine
Fluoxetine
Placebo
5
20
40
94
91
92
77
-0.5(0.02)
-0.4(0.02)
-0.5(0.02)
0.54
0.64
0.65
0.33
Harto et al. [24] DSM-III, Age 18–65
HAM-D ≥ 20
38.4
43.8
36.4
0.37
0.37
0.37
6 Fluoxetine
Fluoxetine
Fluoxetine
Placebo
5
20
40
8
10
9
8
1 (0.3)
1.1 (0.3)
0.9 (0.3)
Byerley et al. [25] DSM-III
HAM-D21 ≥ 20
38.9 0.31 6 Fluoxetine
Placebo
40–80 32
29
-1.1 (0.1) 0.38
0.45
Muijen et al. [26] Research Diagnostic Criteria, Age 18–
65
HAMD-D17 ≥ 17
35.8 0.37 6 Mianserin
Fluoxetine
Placebo
20
20
27
26
28
-1.2 (0.2) 0.55
0.23
0.46
0.43B
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Feighner et al. [27] DSM-III, Age 18–70
HAMD-D21 ≥ 20, RSDM ≥ 8 and 
RSDM ≥ Covi
45 0.26 6 Imipramine
Fluoxetine
Placebo
150
80 (median)
46
51
48
-0.3(0.04) 0.51
0.68
Dunlop et al. [28] DSM-III, Age 18–65
HAMD-D ≥ 14 and RSDM >Covi
39.3
39.3
39.3
6 Fluoxetine
Fluoxetine
Fluoxetine
Placebo
20
40
60
103
99
97
56
-0.1(0.03)
-0.03 (0.03)
0.1(0.03)
0.53
0.51
0.59
0.36
0.35
0.41
0.39
0.34
Valducci et al. [29] DSM-III-R, Age 19–67
HAMD-D >18
0.43 8 Fluoxetine
Placebo
20 20
20
-0.9 (0.1) 0.70
0.25
Heiligenstein et al. 
[31]
DSM-III-R, Age 18–65
HAMD-D17 ≥ 15
44.4 8 Fluoxetine
Placebo
20 46
43
0.1 (0.1)
-0.9 (0.1)
0.61
0.41
Sramek et al. [32] DSM-III-R, Age 18–65
HAMD-D24 ≥ 21 with item 1 ≥ 2, 
HAM-A ≤ 18, HAMD-D24 <HAM-A, 
RSDM ≥ 8 and RSDM >Covi
33.9 0.40 9 ABT-200
Fluoxetine
Placebo
160–320
20
72
72
72
-0.3(0.03) 0.17
0.13
Fava et al. [33] DSM-III-R, Age (mean 41,3) HAMD-
D17 ≥ 18, Raskin depression score ≥ 8 
and superior to Raskin anxiety score
41.3 0.49 12 Paroxetine
Fluoxetine
Placebo
20–50
20–80
55
54
19
0.1 (0.1) 0.57
0.53
Rudolph et al. [34] DSM-IV, Age > 18
HAMD-D21 ≥ 20
40 0.33 8 Venlafaxine
XR
Fluoxetine
Placebo
75–225
20–60
100
103
98
-0.2(0.02) 0.50
0.42
0.27
0.21
Coleman et al. [35] DSM-IV, Age 18–76
HAMD-D21 ≥ 20
37.1 8 Bupropion 
SR
Fluoxetine
Placebo
150–400
20–60
150
154
152
-0.2(0.01) 0.57
0.50
0.37
0.33
Goldstein et al. [9] DSM-IV, Age 18–65
HAMD-D17 ≥ 15 and CGI-S ≥ 4
39.7 0.35 8 Duloxetine
Fluoxetine
Placebo
40–120
20
70
33
70
-0.2(0.04) 0.45
0.39
0.36
0.34
Silverstone et al. [42] DSM-IV, Age ≥ 18
HAMD-D21 ≥ 20 (on the first 17 
items), Covi ≥ 8
43.2 0.4 12 Fluoxetine
Venlafaxine
XR
Placebo
20–60
75–225
121
128
119
-0.6(0.02) 0.62
0.43
0.26
0.40
Globally 40 
± 3
0.39 7 ± 2 Fluoxetine
Placebo
20–80 2078
1093
-0.46(0.11) 0.37(0.09) ** -0.02(0.09) 
**
** Log Odds ratios (SD)
Table 2: Selected studies presentation for fluoxetine (Continued)BMC Psychiatry 2006, 6:30 http://www.biomedcentral.com/1471-244X/6/30
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odds ratio 1.40). This advantage is borderline significant
when adjusting for duration (corresponding odds ratio
1.36). The residual between-study variance was constant.
Whatever the parameter of interest or the adjustment fac-
tor considered, the fact that variances were imputed did
not change the conclusions.
When removing studies one at a time in the analysis set,
the conclusions didn't change except when removing [4]
or [5] where statistical significance is reached -0.27 [-0.50;
-0.01] (Odds ratio 0.76) in favour of duloxetine.
Analyses made on the subgroup of fluoxetine studies
(where the number of analysed patients was greater than
20), gave for the efficacy 0.09 [-0.09;0.26] (13 fluoxetine
studies) still favouring fluoxetine, for the response factor -
0.22 [-0.46;0.02] (10 fluoxetine studies) still favouring
duloxetine and for the dropouts factor -0.02 [-0.33;0.28]
(7 fluoxetine studies) similar results were found.
Diagram Flow for venlafaxine Figure 3
Diagram Flow for venlafaxine.
Potentially relevant RCTs identified and 
screened for retrieval  (n=283) 
Excluded articles (n=228) 
Reasons: 
-  not right population 
-  placebo was not included as a 
reference 
-  long-term study 
RCTs retrieved for more detailed evaluation 
(n=55) 
Excluded articles (n=47) 
Reasons: 
-  Other types of depression: 
Poststroke, seasonal, 
melancholia…
-  Studies with pooled data 
- Studies  with  co-therapy 
-  Studies with no placebo arm 
- Other  problem design: open trials, 
continuation treatment with new 
formulations, fuoxetine 
discontinuated, prediction 
Studies…
RCTs selected for evaluation (n=8) 
RCTs selected by outcome 
Efficacy (n=8) 
Response (n=6) 
Dropouts (n=7) 
Excluded articles  
Reasons: 
-  Missing data BMC Psychiatry 2006, 6:30 http://www.biomedcentral.com/1471-244X/6/30
Page 10 of 15
(page number not for citation purposes)
For duloxetine compared with venlafaxine, cf. [Table 4] inves-
tigating the efficacy score (in the effect size scale) the effect
size varied from 0.16 to 0.25 favouring venlafaxine signif-
icantly in all analyses except when adjusting for sex repar-
tition where the result is borderline significant 0.16 [-
0.01;0.33] though still numerically favouring venlafaxine.
The residual between-study variance is small in all analy-
ses, the model which has the best fit (smallest residual
between-study variance) gave an estimated effect size of
0.25 [0.11;0.40] significantly in favour of venlafaxine.
Investigating the response factor, the odds ratio varied
from 1.75 to 2.46 favouring venlafaxine significantly in all
analyses. The residual between-study variance remained
stable, the best fit (smallest residual between-study vari-
ance) corresponds to an odds ratio of 1.75. Concerning
the dropouts the odds ratio varied from 1.14 to 1.30
throughout adjustments favouring numerically venlafax-
ine in all analyses. The residual between-study variance
remained stable and small.
When removing studies one at a time from the analysis
set, the conclusions didn't change thus favouring robust-
ness in results.
Results: duloxetine compared with fluoxetine and venlafaxine Figure 5
Results: duloxetine compared with fluoxetine and venlafaxine. a efficacy (effect size scale) b response (log odds ratio) 
c dropouts (log odds ratio)
   a         b        c  
Favors Duloxetine                         Favors Comparator 
Response
-1,25 -0,75 -0,25 0,25 0,75 1,25
Favors Duloxetine                        Favors Comparator 
Droupouts
-0,5 -0,3 -0,1 0,1 0,3 0,5
Favors Duloxetine                                     Favors Comparator 
Effect Size
-0,5 -0,3 -0,1 0,1 0,3 0,5
Venlafaxine
Fluoxetine
-0.5 -0.3 -0.1 0.1 0.3 0.5 -1.25  -0.75  -0.25  0.25  0.75  1.25  -0.5  -0.3  -0.1  0.1  0.3  0.5 
Funnel Plots Figure 4
Funnel Plots. a duloxetine b fluoxetine c venlafaxine
a        b         c  
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Table 3: Selected studies presentation for venlafaxine
Study Inclusion criteria Age Percent male duration 
(weeks)
Treatment Dosage (mg/
day)
Patients per 
arm
Effect size (SD) Response (%) Dropouts (%)
Khan et al. [36] DSM-III, HAMD-D ≥ 
20
41
41
41
0.44
0.44
0.44
6V e n l a f a x i n e
Venlafaxine
Venlafaxine
Placebo
75
75–225
150–375
23
22
22
26
-0.8(0.1)
-0.6(0.1)
-0.7(0.1)
0.21
0.15
Schweizer et al. [37] DSM-III-R, Age 24–
63
HAMD-D ≥ 20
46
46
46
0.60
0.60
0.60
6V e n l a f a x i n e
Venlafaxine
Venlafaxine
Placebo
75
225
375
15
15
14
16
-0.6(0.1)
-1.2(0.2)
-1.1(0.2)
0.43
0.57
Cunningham et al. [38] DSM-III-R, Age ≥ 18
HAMD-D ≥ 20
41 0.33 6 Venlafaxine
Trazodone
Placebo
25–200
50–400
72
77
76
-0.4(0.03) 0.72
0.55
0.29
0.36
Schweizer et al. [39] DSM-III-R, Age≥ 18
HAMD-D21 ≥ 20
41 0.31 6 Imipramine
Venlafaxine
Placebo
75–225
75–225
73
73
78
-0.6(0.03) 0.77
0.47
0.36
0.27
Cunningham et al. [40] DSM-III-R, Age ≥ 18
HAMD-D ≥ 20
40
43
0.38
0.39
12 Venlafaxine XR
Venlafaxine IR
Placebo
75–150
75–150
97
96
100
-0.5(0.02)
-0.5(0.02)
0.68
0.52
0.31
0.29
0.40
0.41
Thase et al. [41] DSM-IV, Age ≥ 18
HAMD-D21 ≥ 20
40 0.39 8 Venlafaxine XR
Placebo
75–225 91
100
-0.6(0.02) 0.58
0.29
0.27
0.40
Rudolph et al. [34] DSM-IV, Age ≥ 18
HAMD-D21 ≥ 20
40 0.32 8 Fluoxetine
Venlafaxine XR
Placebo
20–60
75–225
103
100
98
-0.1(0.02) 0.57
0.42
0.19
0.21
Silverstone et al. [42] DSM-IV, Age ≥ 18
HAMD-D21 ≥ 20 
(on the first 17 
items), Covi ≥ 8
41 0.39 12 Fluoxetine
Venlafaxine XR
Placebo
20–60
75–225
121
128
119
-0.4(0.02) 0.67
0.43
0.29
0.40
Globally NA 42 ± 2 0.43 8 ± 3 Venlafaxine
Placebo
75–225 768
613
-0.51(0.07) 1.28(0.26) ** -0.25(0.12) **
** Log Odds ratios (SD)BMC Psychiatry 2006, 6:30 http://www.biomedcentral.com/1471-244X/6/30
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Discussion
The use of the meta-regression method to indirectly com-
pare duloxetine with each active comparator revealed that
there was no significant difference with fluoxetine either
in efficacy or in safety. Findings only suggest that more
patients might respond to duloxetine. Results suggest that
duloxetine might be significantly less effective compared
with venlafaxine, (in terms of treatment effects and
number of response) with similar dropouts rates.
Results given by sensitivity analyses showed relatively
good consistency, as no analysis changed the conclusions.
The results became nonsignificant in one analysis com-
paring venlafaxine with duloxetine, but the estimated
value seldom moved. When removing [4] or [5] from the
analysis set, duloxetine treated patients had statistically
more chance to respond than when treated with fluoxet-
ine. These findings were obtained by removing the less
favourable studies for duloxetine, and we found no differ-
ences in the design or patients' characteristics that may
explain why. These tests showing significance (when com-
paring fluoxetine to duloxetine) or non-significance
(when comparing venlafaxine to duloxetine), as in every
study where multiple testing is performed, may be due to
a drop in statistical power, which can bias the conclu-
sions. As some robust trends have been found between
the different drugs, the findings are considered robust to
the confounding factors that have been investigated.
Our findings should, however, be interpreted with cau-
tion. Findings of superior efficacy by indirect comparisons
are observational and therefore vulnerable to bias. Yet,
several articles have recently shown that indirect compar-
isons adjusted at the aggregate level usually agree with
direct comparisons. An indirect meta-analysis of studies
comparing olanzapine with haloperidol and risperidone
with haloperidol yielded conclusions similar to those
found in a direct comparative randomized clinical trial of
olanzapine and risperidone [43]. Song et al. [44] demon-
strated that the results of adjusted indirect comparisons
were usually similar to those of direct comparisons. In
their study, there were a few significant discrepancies
between the direct and the indirect estimates, although
the direction of discrepancy was unpredictable. The
authors concluded that empirical evidence presented in
their study clearly indicates that in most cases, results of
adjusted indirect comparisons are not significantly differ-
ent from those of direct comparisons.
While we recognize that none of the trials involving
duloxetine used venlafaxine as an active comparator, our
results are in accordance with a recent meta-analysis com-
paring duloxetine and venlafaxine in the treatment of
MDD [45] and a review comparing second-generation
antidepressants [46].
Vis et al. used results of 6 trials with duloxetine and 4 with
venlafaxine to report the efficacy and safety of either ven-
lafaxine or duloxetine compared with placebo. They
found that venlafaxine rates for remission and response
were respectively 17.8% (CI95%  9.0–26.5) and 24.4%
(CI95% 15.0–37.7) greater than placebo, compared with
Table 4: Sensitivity analyses: adjustment for confounding factors
EFFECT RESPONSE DROPOUTS
mean Confidence interval Est. bet. 
st. 
variance
*
mean Confidence interval Est. bet. 
st. 
variance
*
value Confidence interval Est. bet. 
st. 
variance
*
AGE
venlafaxine 0.25 0.11 0.40 0.002 0.90 0.49 1.31 0.049 0.26 -0.09 0.61 0.000
Fluoxetine 0.13 -0.14 0.39 0.097 -0.10 -0.37 0.17 0.000 0.23 -0.14 0.60 0.000
MALE PERCENT
venlafaxine 0.16 -0.01 0.33 0.008 0.66 0.21 1.12 0.096 0.23 -0.13 0.59 0.001
Fluoxetine 0.12 -0.14 0.38 0.010 -0.17 -0.43 0.08 0.000 0.31 -0.02 0.64 0.000
DURATION
venlafaxine 0.23 0.07 0.39 0.009 0.56 0.18 0.95 0.047 0.13 -0.23 0.48 0.000
Fluoxetine 0.10 -0.16 0.36 0.100 -0.21 -0.45 0.03 0.000 0.34 0.02 0.67 0.000
DOSAGE
venlafaxine 0.22 0.06 0.37 0.008 0.70 0.26 1.15 0.096 0.22 -0.12 0.56 0.000
Fluoxetine 0.19 -0.10 0.48 0.094 -0.05 -0.38 0.27 0.000 0.19 -0.19 0.57 0.000
IMPUTATION
venlafaxine 0.22 0.06 0.37 0.008 0.74 0.29 1.18 0.093 0.18 -0.18 0.54 0.000
Fluoxetine 0.11 -0.14 0.36 0.096 -0.20 -0.44 0.04 0.000 0.27 -0.06 0.60 0.000
* estimated between study varianceBMC Psychiatry 2006, 6:30 http://www.biomedcentral.com/1471-244X/6/30
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14.2% (CI95% 8.9–26.5) and 18.6% (CI95% 13.0–24.2) for
duloxetine. Reported adverse events were comparable
between active drugs. The authors concluded that venla-
faxine showed a favorable trend in remission and
response rates compared with duloxetine, but that no sig-
nificant between-drug differences were observed for drop-
out rates and adverse events. Due to the nature of the
methodology used, no objective evidence concerning how
venlafaxine performs when compared with duloxetine
can be drawn. Nonetheless, the numerical trend seen in
this paper is in accordance with the ones found here.
A review of second-generation antidepressants' efficacy in
the treatment of MDD by Hansen et al. [46] found that sig-
nificantly more patients responded to venlafaxine than to
fluoxetine. The relative benefit: 1.12 (CI95% 1.02–1.23)
favoured venlafaxine. This result suggest the same pattern
found here; response rates of venlafaxine are superior to
duloxetine which are equal to fluoxetine
Concerning available comparisons with fluoxetine, of the
9 randomized clinical trials that evaluated the efficacy and
safety of duloxetine, only two used fluoxetine as an active
comparator [4,9]. Neither of these studies was specifically
designed and powered to facilitate head-to-head compar-
isons between duloxetine and fluoxetine. The primary
goal was comparison of duloxetine vs. placebo. These two
studies (powered 65%) were identical parallel group,
double-blind, forced-titration active- and placebo-con-
trolled studies comparing duloxetine titrated from 20 mg
to 60 mg BID with placebo over 8 weeks of acute treat-
ment. A fluoxetine 20 mg QD arm was used as an internal
active comparator standard. In these studies, duloxetine
was statistically significantly superior to placebo on the
primary analysis (mean change analysis from baseline of
the HAMD-17 total score) and for some of the secondary
endpoints. There was no statistically significant difference
between fluoxetine and placebo for mean change in
HAMD-17 total score in any of the studies. The fluoxetine
treatments groups were underpowered qualitative control
arms: [1] half patients included compared with duloxet-
ine and placebo reaching low numbers (33 [9] and 37
[4]), [2] comparison of a fixed dose at the minimum rec-
ommended range for fluoxetine (20 mg/day) with the
highest tested dose for duloxetine (120 mg/day). Higher
doses of fluoxetine may have proven more effective and a
more robust comparison of duloxetine, and fluoxetine
should include a broader and more optimal dose range
for comparison. Furthermore, as fluoxetine has proven to
have an effect when compared with placebo [47,48], these
direct comparisons are not sufficient to draw conclusions
about duloxetine's superiority over fluoxetine.
Superiority of one antidepressant medication relative to
another needs to be established by means of prospectively
designed, adequately powered, head-to-head clinical tri-
als. As the results of placebo-controlled trials are often suf-
ficient to acquire the regulatory approval of new drugs,
pharmaceutical companies may not be motivated to sup-
port trials that compare new drugs with existing active
treatments. Lack of evidence from direct comparison
between active interventions makes it difficult for clini-
cians to choose the most effective treatment for patients
[49]. Because of the lack of direct evidence, indirect com-
parisons have been recommended [50]. Adjusted indirect
comparison is a way to compare two compounds through
their relative effect vs. a common comparator (placebo in
our study). The indirect approach to meta-analysis
requires certain conditions to yield optimal results. Differ-
ences in study designs, inclusion/exclusion criteria,
patients characteristics at baseline as well as difference in
drug dosage [48] and publication bias are limitations that
may lead to unbalanced conclusions [43] and merit dis-
cussion.
Our study had some limitations. First, the time frame dif-
fers between active drugs. Because fluoxetine is the oldest
antidepressant compared with venlafaxine and duloxet-
ine, inclusion criteria for MDD was based on DSM III or
IIIr criteria (not DSM IV) in the majority of the fluoxetine
studies compared with those of venlafaxine and duloxet-
ine. Secondly, sample sizes seem to be smaller for the
fluoxetine studies and include patients with lower HAM-
D score (14 to 19). Thirdly the patients characteristics,
even if they vary only slightly can act as confounding fac-
tors and bias the results. Fourthly, dosages varied between
studies and between drugs. Lastly, the missing data might
not be balanced between treatments. All these sources of
heterogeneity could lead to bias. Considering that the
computation of an effect size included adjustment for
baseline severity differences and that influence of patient
characteristics and study designs were assessed through
sensitivity analyses, some confidence can be put on the
results if they show stability over the different analyses.
Also, the random effect nature of the model used here
should be able to deal with the remaining amount of bias
that couldn't be measured or properly modelled. Finally,
the other major issue in any meta-analysis is the potential
publication bias. Publication bias is a major source of sys-
tematic bias in overviews, where trials with positive results
are more likely to be published than those with neutral or
negative results, especially if the trials are small. We there-
fore tested for publication bias using the Egger test for fun-
nel plot asymmetry [51]. Ruling out completely
publication bias is nearly impossible. Even so, any bias
would most likely be in favour of the newer drug and its
existence would not undermine the results presented here
[52].BMC Psychiatry 2006, 6:30 http://www.biomedcentral.com/1471-244X/6/30
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Conclusion
In the absence of a well-powered randomised placebo
controlled direct comparison trial, meta-regression analy-
sis offers the most rigorous evidence science can buy. Even
if it's true that the level of evidence provided by indirect
comparisons is lower than the level provided by direct
comparisons; in some cases [43] indirect comparisons
have actually been able to predict the results of head-to
head-clinical trials. The capacity of prediction is nonethe-
less directly linked to the quality of the methodology used
and the information available. Both have been discussed
in the core of this paper, and in this context the results
seem stable enough to be confident that the bias are con-
trolled and that the results provide valuable additional
information to health care professionals, health econo-
mists and the pharmaceutical industry. These results sug-
gest evidence of venlafaxine superiority compared with
duloxetine and absence of a difference between fluoxetine
and duloxetine. In any case, investigating the relative effi-
cacy of duloxetine compared directly with other existing
antidepressants – particularly venlafaxine – in a well-
designed trial would be welcomed to challenge or rein-
force our findings.
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